Aastrom Ticker Symbol Reverts to ASTM
18 March 2010 - 11:30PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM) today reported that its
ticker symbol will revert back to ASTM as of March 18, 2010. As a
result of the company's reverse stock split which became effective
as of February 18, 2010, the company's common stock had been
trading on a post-split basis under the temporary trading symbol
"ASTMD" for approximately 20 trading days.
About Aastrom Biosciences
Aastrom Biosciences is developing autologous cellular therapies
for use in the treatment of severe cardiovascular diseases. The
company's proprietary cell-processing technology enables the
production of cellular therapies using a patient's own bone marrow
that can be delivered directly to damaged tissues. Aastrom has
advanced this technology into late-stage clinical development and
is conducting two Phase 2 clinical trials to treat dilated
cardiomyopathy and a Phase 2b clinical trial to treat critical limb
ischemia. For more information, please visit Aastrom's website at
www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports
on Form 10-Q and other filings with the Securities and Exchange
Commission.
CONTACT: Berry & Company
Media:
Stephen Zoegall
(212) 253-8881
szoegall@berrypr.com
Aastrom Biosciences
Investors:
Kimberli O'Meara
(734) 930-5777
ir@aastrom.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024